Erdosteine

Summary

Erdosteine (CHEMBL1697744) is an approved small molecule (ATC R05CB15); indicated across 2 conditions including chronic obstructive pulmonary disease and chronic bronchitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R05CB15
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 249.3 Da · C8H11NO4S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1697744
Name	Erdosteine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	65632
ATC	R05CB15
Molecular formula	C8H11NO4S2
Molecular weight	249.3
InChIKey	QGFORSXNKQLDNO-UHFFFAOYSA-N

SMILES: C1CSC(=O)C1NC(=O)CSCC(=O)O

IUPAC name: 2-[2-oxo-2-[(2-oxothiolan-3-yl)amino]ethyl]sulfanylacetic acid

Also known as: Erdosteina, Erdosteine, Mucotec, RV-144, RV144, SID124896662, SID170465586, SID144206727, ERDOSTEINE, Dithiosteine, erdosteine

Patent coverage: 1,019 distinct patent families (3,846 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
chronic bronchitis	2	MONDO:0005607	EFO:0006505

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	1
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01176318	PHASE4	WITHDRAWN	Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Erdosteine for Treatment of Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
NCT01032304	PHASE3	UNKNOWN	The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)
NCT07242222	PHASE1/PHASE2	RECRUITING	Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease
NCT00338507	PHASE2	COMPLETED	Phase 2 Study - Erdosteine in Patients With CB/COPD
NCT07329946	Not specified	NOT_YET_RECRUITING	Immuno-inflammatory Response of Erdosteine in COPD

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).